In vitro activity of isavuconazole against clinically isolated yeasts from Chile

• Published in: Brazilian journal of microbiology Vol. 51; no. 4; pp. 1801 - 1805
• Main Authors: Álvarez Duarte, Eduardo, Salas, Valentina
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.12.2020
• Subjects: Biomedical and Life Sciences; Clinical Microbiology - Short Communication; Food Microbiology; Life Sciences; Medical Microbiology; Microbial Ecology; Microbial Genetics and Genomics; Microbiology; Mycology; Isavuconazole; Triazoles; Antifungal agents; Minimum inhibitory concentration
• ISSN: 1517-8382; 1678-4405
• DOI: 10.1007/s42770-020-00333-x

Isavuconazole is the last antifungal agent approved by the FDA and available for treatment of fungal infections. In the present study, the in vitro activity of isavuconazole against several yeasts was investigated. Two hundred forty-six isolates were included: 64 Candida albicans , 53 Candida parapsilosis sensu stricto, 48 Cryptococcus neoformans species complex, 27 C. glabrata sensu stricto, 17 C. lusitaniae , 17 C. tropicalis , 5 C . orthopsilosis , 4 C. krusei , 3 C. guilliermondii sensu stricto, 3 C. pelliculosa , 2 C . dubliniensis , 1 C . auris , 1 C . fermentati and 1 Trichosporon asahii . All isolates were recovered from clinical isolates from Chile, being 221 from hemoculture, 22 from cerebrospinal fluid, 1 pleural fluid, and 1 from tissue culture. The minimal inhibitory concentrations (MICs) and minimal fungicidal concentrations (MFCs) of isavuconazole were determined. Isavuconazole demonstrated good in vitro activity against all species tested. MIC90 values and MFC ranges of isavuconazole for Candida albicans were 0.03 mg/L and 0.03– > 16 mg/L respectively. Non– Candida albicans species isolates were inhibited by ≤ 1 mg/L, with MFC ranges from < 0.03– > 16 mg/L. Also, isavuconazole was active against the non- Candida yeasts, being inhibited with MIC values ≤ 0.06 mg/L. Isavuconazole has exhibited potent in vitro activity against clinical isolates of Candida spp., Cryptococcus neoformans species complex, and other clinical yeast in Chile. Despite the results obtained in the present work, additional clinical studies are necessary to verify the level of efficacy of this azole.